Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
15
MRVI Quote, Financials, Valuation and Earnings
Last price:
$5.38
Seasonality move
:
12.9%
Day range:
$5.32 - $5.62
52-week range:
$4.28 - $11.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.63x
P/B ratio:
2.21x
Volume:
2.5M
Avg. volume:
2.3M
1-year change:
-15.62%
Market cap:
$762.4M
Revenue:
$288.9M
EPS (TTM):
-$1.64
Analysts' Opinion
-
Consensus RatingMaravai LifeSciences Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.07, Maravai LifeSciences Holdings has an estimated upside of 68.8% from its current price of $5.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.25 representing 20.93% downside risk from its current price of $5.38.
Fair Value
-
According to the consensus of 14 analysts, Maravai LifeSciences Holdings has 68.8% upside to fair value with a price target of $9.07 per share.
MRVI vs. S&P 500
-
Over the past 5 trading days, Maravai LifeSciences Holdings has underperformed the S&P 500 by -3.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Maravai LifeSciences Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Maravai LifeSciences Holdings revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Maravai LifeSciences Holdings reported revenues of $65.2M.
Earnings Growth
-
Maravai LifeSciences Holdings earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Maravai LifeSciences Holdings reported earnings per share of -$0.70.
Enterprise value:
974M
EV / Invested capital:
0.86x
Price / LTM sales:
2.63x
EV / EBIT:
1.98x
EV / Revenue:
3.52x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-83.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.78x
Gross Profit (TTM):
$128.4M
Return On Assets:
-14.17%
Net Income Margin (TTM):
-81.13%
Return On Equity:
-29.18%
Return On Invested Capital:
-17.37%
Operating Margin:
-23.09%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $906.7M | $419.5M | $276.9M | $66.9M | $65.2M | |
| Gross Profit | $751.9M | $252.6M | $128.4M | $30.2M | $28.4M | |
| Operating Income | $611.7M | $84.8M | -$49.9M | -$13M | -$15.1M | |
| EBITDA | $654.7M | $143.9M | $548.4M | $4.2M | -$148M | |
| Diluted EPS | $1.79 | $0.18 | -$1.64 | -$0.05 | -$0.70 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $145.6M | $687.5M | $835.5M | $700.9M | $679.1M | |
| Total Assets | $649.5M | $1.9B | $2.2B | $2.3B | $1.3B | |
| Current Liabilities | $280.5M | $114.4M | $115.7M | $78.3M | $63.2M | |
| Total Liabilities | $702.1M | $1.4B | $1.4B | $1.4B | $665.1M | |
| Total Equity | -$52.6M | $453.6M | $841.7M | $892.3M | $613.1M | |
| Total Debt | $351.7M | $531.6M | $528.3M | $525M | $521.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $495.4M | $217.8M | $29.9M | $14.2M | $13.1M | |
| Cash From Investing | -$254.7M | -$127.9M | -$32.3M | -$15.5M | -$9M | |
| Cash From Financing | -$171M | -$127.7M | $947K | $783K | $809K | |
| Free Cash Flow | $478.9M | $162.8M | -$11.7M | -$1.7M | $3.5M | |
MRVI
Sector
Market Cap
$762.4M
$44.6M
Price % of 52-Week High
46.52%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-15.62%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.61
200-day SMA
Sell
Level
$7.98
Bollinger Bands (100)
Sell
Level
5.99 - 9.01
Chaikin Money Flow
Sell
Level
-68.5M
20-day SMA
Sell
Level
$5.53
Relative Strength Index (RSI14)
Sell
Level
43.68
ADX Line
Sell
Level
11.13
Williams %R
Neutral
Level
-68.1373
50-day SMA
Sell
Level
$6.33
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
28.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1745)
Buy
CA Score
(Annual)
Level (0.0575)
Buy
Beneish M-Score
(Annual)
Level (-4.0665)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-3.3387)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Stock Forecast FAQ
In the current month, MRVI has received 8 Buy ratings 6 Hold ratings, and 0 Sell ratings. The MRVI average analyst price target in the past 3 months is $9.07.
-
Where Will Maravai LifeSciences Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Maravai LifeSciences Holdings share price will rise to $9.07 per share over the next 12 months.
-
What Do Analysts Say About Maravai LifeSciences Holdings?
Analysts are divided on their view about Maravai LifeSciences Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Maravai LifeSciences Holdings is a Sell and believe this share price will drop from its current level to $4.25.
-
What Is Maravai LifeSciences Holdings's Price Target?
The price target for Maravai LifeSciences Holdings over the next 1-year time period is forecast to be $9.07 according to 14 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is MRVI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Maravai LifeSciences Holdings is a Buy. 8 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRVI?
You can purchase shares of Maravai LifeSciences Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Maravai LifeSciences Holdings shares.
-
What Is The Maravai LifeSciences Holdings Share Price Today?
Maravai LifeSciences Holdings was last trading at $5.38 per share. This represents the most recent stock quote for Maravai LifeSciences Holdings. Yesterday, Maravai LifeSciences Holdings closed at $5.38 per share.
-
How To Buy Maravai LifeSciences Holdings Stock Online?
In order to purchase Maravai LifeSciences Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
